drugset / Trial / NCT06334432
Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
NUV-1511-01 is a first-in human, open- label, Phase 1/2 to evaluate the safety and efficacy of NUV-1511 in patients with advanced solid tumors. The Phase 1 portion include patients with advanced solid tumors and is designed to determine the safety and the tolerability of doses of NUV-1511. In Phase 2, NUV-1511 will be given to determine the efficacy of patients with advanced solid tumors.
Timeline
- Start
- 2024-03-14
- Primary completion
- 2027-03
- Completion
- 2027-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NUV-1511 | Small molecule | — | — |